A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

By C. O'Brien, A. Pollett, S. Gallinger, J. Dick. Nature, 2007

4,313 citations recorded by the source corpus.

Subfields: Biotechnology, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/631cc923747dbaaa54170e048f2846e109ca6440

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

Jane E. Visvader

In Hepatology

In Oncology

Citations in the corpus

Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “The ultimate test of tumor initiation for leukemia and solid tumor cells (Lapidot et al., 1994; Al-Hajj et al., 2003; Li et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Schatton et al., 2008; Singh et al., 2004) is engraftment capability and tumor growth of the most tumorigenic or…”
Prominin1 marks intestinal stem cells that are susceptible to neoplastic transformation (2008, positive): “CSC of brain7,16, gut3,4 and pancreatic17 tumors have been isolated using PROM1 antibodies; however, most PROM1 antibodies recognize glycosylation-dependent epitopes that vary with the differentiation and transformation status of the cell18, complicating the use of these reagents to fractionate…”
Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. (2011, background): “Whether the more recent discovery of pluripotent colon cancer stem cells may also play a role in relapse following AC awaits further investigation.(29-31) Thus, preclinical tumor growth and kinetic models support a hypothesis that chemotherapy is most effective if initiated promptly when tumor burde”
Mechanisms and insights into drug resistance in cancer (2013, background): “First, the emergence of a dominant cellular population after drug selection since it possesses some favorable characteristics such as a mutated drug binding site (Zhang et al., 2006; O’Brien et al., 2007; Ricci-Vitiani et al., 2007).”
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment (2010, background): “CSCs have been identified by using several markers, such as CD133 and CD166 (Ref”
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment (2018, background): “Several cell surface markers have been verified to identify CSCenriched populations, such as CD133, CD24, CD44, EpCAM (epithelial cell adhesion molecule), THY1, ABCB5 (ATP-binding cassette B5), and CD200 [27, 32, 34, 52].”
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. (2014, background): “CD44v6 Expression Demarcates a Highly Tumorigenic CR-CSC Population with Metastatic Potential We and others previously demonstrated that CR-CSCs are enriched in tumor spheres or freshly isolated CD133 cells (O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Todaro et al., 2007).”
Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 (2009, methodology): “Based on previous published reports regarding CSCs in solid tumors [7–21], the following markers were studied: CD24, CD44, CD133, and CD166.”
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. (2010, neutral): “Similar findings have been reported for cancers of the breast, brain, colon, ovary, pancreas, and prostate (Al-Hajj et al., 2003; Li et al., 2007; O’Brien et al., 2007; Singh et al., 2003; Zhang et al., 2008b).”
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010, background): “These cancer stem cells (CSCs) can self-renew and differentiate to generate the cellular heterogeneity of the originating tumor (Lapidot et al., 1994; Al-Hajj et al., 2003; Singh et al., 2004; Hermann et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007).”